-+ 0.00%
-+ 0.00%
-+ 0.00%

IMMIX BIOPHARMA’S NXC-201 NEXICART-2 INTERIM CLINICAL TRIAL RESULTS SELECTED FOR ORAL PRESENTATION AT ASH 2026

Reuters·11/04/2026 14:15:00

Please log in to view news